Abstract
Increasing evidence suggests that the SYT-SSX fusion gene plays an important role in synovial sarcoma development and progression. However, very little is known about the downstream targets of SYT-SSX. In this study, we used antisense oligonucleotides to block the expression of the SYT-SSX fusion gene in synovial sarcoma cells. By comparing SYT-SSX inhibited cells with noninhibited cells, the gene expression profile was analysed using cDNA microarray and established by real-time PCR. Herewith, using a filter containing 1176 cancer-relevant genes, we found that the DNA repair gene XRCC4 and the DNA mismatch repair gene MSH2 were downregulated, whereas the gene encoding for the serine/threonine protein kinase PRK (also known as CNK), and the macrophage inhibitory cytokine MICI (also known as PLAB) were upregulated after the inhibition of SYT-SSX. In comparison, expression of the XRCC4 gene was undergoing the strongest alteration. Consistently, the protein expression of XRCC4 was found to be decreased after SYT-SSX inhibition, whereas there were no detectable changes for the other gene products. Our study provides some clues to elucidate the signaling pathways of the SYT-SSX fusion gene, as well as it demonstrates a valuable model system for search for other SYT-SSX targets.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
28 November 2022
An Editorial Expression of Concern to this paper has been published: https://doi.org/10.1038/s41388-022-02552-y
References
Brett D, Whitehouse S, Antonson P, Shipley J, Cooper C and Goodwin G . (1997). Hum. Mol. Genet., 6, 1559–1564.
Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, Gusterson BA and Cooper CS . (1994). Nat. Genet., 7, 502–508.
Crew AJ, Clark J, Fisher C, Gill S, Grimer R, Chand A, Shipley J, Gusterson BA and Cooper CS . (1995). EMBO J., 14, 2333–2340.
de Leeuw B, Balemans M, Olde Weghuis D and Geurts van Kessel A . (1995). Hum. Mol. Genet., 4, 1097–1099.
dos Santos NR, de Bruijn DR and van Kessel AG . (2001). Genes Chromosomes Cancer, 30, 1–14.
Ferguson DO and Alt FW . (2001). Oncogene, 20, 5572–5579.
Gao Y, Ferguson DO, Xie W, Manis JP, Sekiguchi J, Frank KM, Chaudhuri J, Horner J, DePinho RA and Alt FW . (2000). Nature, 404, 897–900.
Gao Y, Sun Y, Frank KM, Dikkes P, Fujiwara Y, Seidl KJ, Sekiguchi JM, Rathbun GA, Swat W, Wang J, Bronson RT, Malynn BA, Bryans M, Zhu C, Chaudhuri J, Davidson L, Ferrini R, Stamato T, Orkin SH, Greenberg ME and Alt FW . (1998). Cell, 95, 891–902.
Inagaki H, Nagasaka T, Otsuka T, Sugiura E, Nakashima N and Eimoto T . (2000). Mod. Pathol., 13, 482–488.
Khanna KK and Jackson SP . (2001). Nat. Genet., 27, 247–254.
Ladanyi M . (2001). Oncogene, 20, 5755–5762.
Myers KJ and Dean NM . (2000). Trends Pharmacol. Sci., 21, 19–23.
Nagai M, Tanaka S, Tsuda M, Endo S, Kato H, Sonobe H, Minami A, Hiraga H, Nishihara H, Sawa H and Nagashima K . (2001). Proc. Natl. Acad. Sci. USA, 98, 3843–3848.
Nilsson G, Skytting B, Xie Y, Brodin B, Perfekt R, Mandahl N, Lundeberg J, Uhlen M and Larsson O . (1999). Cancer Res., 59, 3180–3184.
Roth DB and Gellert M . (2000). Nature, 404, 823–825.
Skytting B, Nilsson G, Brodin B, Xie Y, Lundeberg J, Uhlen M and Larsson O . (1999). J. Natl. Cancer Inst., 91, 974–975.
Thaete C, Brett D, Monaghan P, Whitehouse S, Rennie G, Rayner E, Cooper CS and Goodwin G . (1999). Hum. Mol. Genet., 8, 585–591.
Xie Y, Skytting B, Nilsson G, Gasbarri A, Haslam K, Bartolazzi A, Brodin B, Mandahl N and Larsson O . (2002b). Cancer Res., 62, 3861–3867.
Xie Y, Skytting B, Nilsson G, Grimer RJ, Mangham CD, Fisher C, Shipley J, Bjerkehagen B, Myklebost O and Larsson O . (2002a). Oncogene, 21, 5791–5796.
Acknowledgements
This project was supported by grants from the Swedish Cancer Society, the Stockholm Cancer Society and the Swedish Children Cancer Society.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Xie, Y., Törnkvist, M., Aalto, Y. et al. Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene. Oncogene 22, 7628–7631 (2003). https://doi.org/10.1038/sj.onc.1207153
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207153
Keywords
This article is cited by
-
The Effect of SYT-SSX and Extracellular Signal-Regulated Kinase (ERK) on Cell Proliferation in Synovial Sarcoma
Pathology & Oncology Research (2011)
-
Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals
Cancer Immunology, Immunotherapy (2007)
-
IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1
Oncogene (2006)
-
Diagnosis and Management of Synovial Sarcoma
Current Treatment Options in Oncology (2005)
-
Repair of radiation damage to DNA
British Journal of Cancer (2004)